Achievement of complete morphological regression in the use of trastuzumab in patients with inoperable locally advanced Her-2+ breast cancer

Por K. R. Zeinalova, Ya. V. Vishnevskaya, I. P. Ganshina
Publicado em 2014-07-01

Assessment of the receptor status in primary breast cancer with synchronous loco regional metastases: prognostic and clinical role?

Por O. O. Gordeeva, L. G. Zhukova, I. V. Kolyadina, I. P. Ganshina
Publicado em 2019-04-01

Ribociclib in 1st line HR+ breast cancer treatment

Por L G Zhukova, I P Ganshina, O O Gordeeva, E V Lubennikova
Publicado em 2018-06-01

Optimal duration of adjuvant trastuzumab therapy in patients with HER2-possitive early breast cancer: whether the problem is resolved?

Por L G Zhukova, I P Ganshina, E I Khatkova, T E Tikhomirova, O E Kondratyeva
Publicado em 2018-06-01

Olaparib in the metastatic HER2-negative breast cancer setting

Por L. G. Zhukova, E. I. Khatkova, I. P. Ganshina, I. V. Kolyadina, E. V. Lubennikova
Publicado em 2020-12-01

Dermatomyositis and polymyositis in breast cancer patients: a case reports

Por I P Ganshina, L G Zhukova, E Z Burnevitch, O O Gordeeva, O E Kondratieva
Publicado em 2018-03-01

Ribociclib for the treatment of hormone-positive HER2-negative breast cancer

Por I. P. Ganshina, D. A. Filonenko, O. O. Gordeeva, E. V. Lubennikova, I. V. Kolyadina, A. A. Mescheryakov
Publicado em 2019-06-01

Clinical and morphological aspects of neoadjuvant chemotherapy efficacy in patients with aggressive luminal HER2-negative breast cancer

Por D.  A. Morozov, I. V. Kolyadina, I. V. Poddubnaya, I.  P. Ganshina, S. V. Khokhlova, V. V. Kometova, V. V. Rodionov
Publicado em 2022-01-01

ASSOCIATION OF NKT- AND ACTIVATED CD25⁺ PERIPHERAL BLOOD LYMPHOCYTES WITH DISEASE FREE AND OVERALL SURVIVAL OF TRIPLE NEGATIVE BREAST CANCER PATIENTS

Por A. I. Chertkova, E. G. Slavina, T. N. Zabotina, Z. G. Kadagidze, E. K. Shoua, O. O. Gordeeva, I. V. Kolyadina, L. G. Zhukova, I. P. Gan’shina, A. A. Meshcheryakov
Publicado em 2020-12-01

Efficacy and safety of cisplatin and paclitaxel (PlaTax regimen) in the neoadjuvant treatment of patients with stage II–III triple-negative breast cancer

Por O. O. Gordeeva, I. V. Kolyadina, L. G. Zhukova, I. P. Ganshina, G. V. Vyshinskaya, M. A. Kazantseva, M. V. Sukhova, O. E. Ryabishina, E. V. Lubennikova, D. A. Filonenko, E. I. Chichikov, I. N. Polushkina, E. I. Borisova, A. N. Lud, A. A. Meshcheryakov
Publicado em 2020-11-01

EXPERIENCE WITH SUBCUTANEOUS TRASTUZUMAB USED IN RUSSIAN FEDERATION

Por E. V. Lubennikova, I. P. Ganshina, A. N. Lud, D. V. Komov, I. V. Kolyadina, Y. V. Vishnevskaya, I. K. Vorotnikov, D. L. Stroyakovsky, N. A. Savelov, V. F. Semiglazov, А. G. Manikhas, А. V. Osheychik, T. B. Strelnikova, K. R. Zeynalova, L. G. Zhukova
Publicado em 2017-11-01

Russian multicenter experience of using talazoparib in the treatment of patients with BRCA-associated metastatic breast cancer

Por T. Yu. Semiglazova, E. V. Lubennikova, L. V. Bolotina, R. V. Orlova, F. V. Moiseenko, A. V. Avramenko, E. V. Artemeva, S. A. Borozdina, A. A. Vakhitova, N. M. Volkov, I. P. Ganshina, Sh. A. Dzhalilova, L. G. Zhukova, B. S. Kasparov, A. A. Kachmazov, V. V. Klimenko, A. i. Kornietskaya, A. A. Meshcheryakov, A. A. Paichadze, A. N. Poltoratsky, O. E. Ryabishina, M. L. Stepanova, E. N Imyanitov
Publicado em 2020-12-01